Werewolf Therapeutics (HOWL) Competitors $1.93 -0.12 (-5.85%) (As of 11/14/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends HOWL vs. ACET, STTK, RANI, RAIN, XLO, DSGN, VYGR, KMDA, CMPS, and JSPRShould you be buying Werewolf Therapeutics stock or one of its competitors? The main competitors of Werewolf Therapeutics include Adicet Bio (ACET), Shattuck Labs (STTK), Rani Therapeutics (RANI), Rain Oncology (RAIN), Xilio Therapeutics (XLO), Design Therapeutics (DSGN), Voyager Therapeutics (VYGR), Kamada (KMDA), COMPASS Pathways (CMPS), and Jasper Therapeutics (JSPR). These companies are all part of the "medical" sector. Werewolf Therapeutics vs. Adicet Bio Shattuck Labs Rani Therapeutics Rain Oncology Xilio Therapeutics Design Therapeutics Voyager Therapeutics Kamada COMPASS Pathways Jasper Therapeutics Werewolf Therapeutics (NASDAQ:HOWL) and Adicet Bio (NASDAQ:ACET) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations, risk and community ranking. Do institutionals and insiders believe in HOWL or ACET? 64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 83.9% of Adicet Bio shares are held by institutional investors. 21.1% of Werewolf Therapeutics shares are held by insiders. Comparatively, 19.1% of Adicet Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate HOWL or ACET? Werewolf Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 521.76%. Adicet Bio has a consensus price target of $7.50, indicating a potential upside of 614.29%. Given Adicet Bio's higher probable upside, analysts clearly believe Adicet Bio is more favorable than Werewolf Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Adicet Bio 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media prefer HOWL or ACET? In the previous week, Werewolf Therapeutics had 8 more articles in the media than Adicet Bio. MarketBeat recorded 19 mentions for Werewolf Therapeutics and 11 mentions for Adicet Bio. Werewolf Therapeutics' average media sentiment score of 0.94 beat Adicet Bio's score of 0.16 indicating that Werewolf Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Werewolf Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adicet Bio 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in HOWL or ACET? Adicet Bio received 269 more outperform votes than Werewolf Therapeutics when rated by MarketBeat users. However, 68.18% of users gave Werewolf Therapeutics an outperform vote while only 58.86% of users gave Adicet Bio an outperform vote. CompanyUnderperformOutperformWerewolf TherapeuticsOutperform Votes3068.18% Underperform Votes1431.82% Adicet BioOutperform Votes29958.86% Underperform Votes20941.14% Which has more volatility & risk, HOWL or ACET? Werewolf Therapeutics has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Adicet Bio has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Which has higher valuation & earnings, HOWL or ACET? Werewolf Therapeutics has higher earnings, but lower revenue than Adicet Bio. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWerewolf Therapeutics$19.94M4.31-$37.37M-$1.53-1.26Adicet Bio$24.99M3.46-$142.66M-$1.71-0.61 Is HOWL or ACET more profitable? Adicet Bio has a net margin of 0.00% compared to Werewolf Therapeutics' net margin of -578.80%. Adicet Bio's return on equity of -53.85% beat Werewolf Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics-578.80% -58.83% -38.45% Adicet Bio N/A -53.85%-46.45% SummaryWerewolf Therapeutics beats Adicet Bio on 9 of the 17 factors compared between the two stocks. Ad Porter & CompanyWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Werewolf Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HOWL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HOWL vs. The Competition Export to ExcelMetricWerewolf TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$86.00M$7.02B$5.35B$8.88BDividend YieldN/A8.03%4.98%4.04%P/E Ratio-1.2611.36132.0617.45Price / Sales4.31376.471,259.5098.78Price / CashN/A49.2239.0436.42Price / Book0.969.076.265.86Net Income-$37.37M$153.49M$118.56M$224.86M7 Day Performance-13.84%-2.21%-2.16%-0.94%1 Month Performance-1.53%7.48%2.44%3.65%1 Year Performance-12.27%37.84%35.47%26.39% Werewolf Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HOWLWerewolf Therapeutics3.6474 of 5 stars$1.93-5.9%$12.00+521.8%-7.7%$86.00M$19.94M-1.2640Short Interest ↑Analyst RevisionNews CoverageGap UpACETAdicet Bio2.9978 of 5 stars$1.05-7.9%N/A-3.4%$86.52M$24.99M-0.6190Analyst RevisionSTTKShattuck Labs2.9722 of 5 stars$1.37+12.3%N/A-35.4%$65.39M$1.66M-0.74100Analyst ForecastGap UpRANIRani Therapeutics3.6947 of 5 stars$2.35-4.9%N/A+26.7%$125.51M$2.72M-1.99110Short Interest ↓Gap DownRAINRain OncologyN/A$1.21flatN/AN/A$44.02MN/A-0.5963XLOXilio Therapeutics2.5091 of 5 stars$0.96-4.0%N/A-29.7%$42.08MN/A-0.5673Short Interest ↑DSGNDesign Therapeutics0.5634 of 5 stars$6.02-19.7%N/A+265.9%$340.85MN/A-7.0840News CoveragePositive NewsVYGRVoyager Therapeutics4.5445 of 5 stars$6.22-7.0%N/A+6.5%$339.20M$143.77M8.76100Analyst ForecastKMDAKamada3.987 of 5 stars$5.86-2.8%N/A+25.9%$336.83M$142.52M21.70360Analyst ForecastShort Interest ↑CMPSCOMPASS Pathways2.9338 of 5 stars$4.89-1.8%N/A-5.5%$334.57MN/A-2.22120Short Interest ↓JSPRJasper Therapeutics2.7051 of 5 stars$22.10-3.1%N/A+247.1%$333.71MN/A-4.6620 Related Companies and Tools Related Companies Adicet Bio Alternatives Shattuck Labs Alternatives Rani Therapeutics Alternatives Rain Oncology Alternatives Xilio Therapeutics Alternatives Design Therapeutics Alternatives Voyager Therapeutics Alternatives Kamada Alternatives COMPASS Pathways Alternatives Jasper Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HOWL) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Werewolf Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Werewolf Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
